OS THERAPIES INCORPORATED Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
OS THERAPIES INCORPORATED (OSTX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $2.90 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2026-08-14
- OS THERAPIES INCORPORATED adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2025-06-30 was $2.90M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month |
|---|---|
| 2025-06-30 | $2.90M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |